[Effectiveness and safety of immunosuppressive agents in the treatment of rheumatoid arthritis]. 1986

P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
September 1971, The Journal of the Medical Society of New Jersey,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
August 1973, Minerva medica,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
July 1971, Nordisk medicin,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
January 1978, Terapevticheskii arkhiv,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
January 1970, Reumatismo,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
May 2018, American family physician,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
January 1981, Vojnosanitetski pregled,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
April 2006, Rheumatology (Oxford, England),
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
January 1969, Verhandlungen der Deutschen Gesellschaft fur Rheumatologie,
P E Carreira Delgado, and J J Gómez-Reino Carnota, and L Morillas López, and I Ibero Díaz, and I Mateo Bernardo
September 1988, Drugs,
Copied contents to your clipboard!